RxDoctor Payments Data

Eula Geralyn Tetangco, MD

Gastroenterology · Henderson, KYNPI 1639584014

Payments from drug & device makers

$1,630in general payments, 2019–2025

Across 74 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$657
  • Pfizer$228
  • Johnson & Johnson$151
  • Boston Scientific$124
  • Janssen Scientific Affairs, LLC$89
  • Takeda Pharmaceuticals U.S.A., Inc.$76
  • plus $305 from 9 others

What the payments were for

  • Food & beverage$1,630100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,630 in reported general payments places this provider in the 30th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$147,505
Medicare patients
514
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$735,676
OcalivaObeticholic Acid13$120,647
XifaxanRifaximin17$50,439
LinzessLinaclotide43$40,155
VoqueznaVonoprazan Fumarate16$11,109
Mesalamine18$10,812
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates126$8,743
ClenpiqSod Picosulf/Mag Ox/Citric Ac39$6,591
SutabSod Sulf/Pot Chloride/Mag Sulf29$4,706
Ursodiol24$4,649
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C23$3,190
Colestipol Hcl25$2,994
Mesalamine ErMesalamine25$2,292
Omeprazole214$1,782
Tenofovir Disoproxil Fumarate18$1,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$151$735,67621 claims
Intercept Pharmaceuticals, Inc.Ocaliva$65$120,64713 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$22$53,62940 claims
AbbVieLinzess$657$40,15543 claims
Phathom Pharmaceuticals, Inc.Voquezna$42$11,10916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Henderson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →